{"schema_version":"secwatch.filing_event.v1","accession":"0001479290-24-000099","form_type":"8-K","ticker":null,"cik":"0001479290","company_name":"Revance Therapeutics, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.598827+00:00","generated_at":"2026-06-02T05:31:23.683168+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Revance Q1 product revenue $51.7M (+13% YoY); launches Daxxify for cervical dystonia","bullets":["Total net product revenue (DAXXIFY + RHA) $51.7M, up 13% YoY; DAXXIFY net $22.1M after $2M coupon.","DAXXIFY aesthetic units sold +105% YoY; toxin market share 3.7% (up from 3.0% in Q4).","Net loss from continuing ops $49.5M, comparable to $48.5M a year ago; cash $277.1M.","FY 2024 guidance: total net product revenue at least $280M; funded to cash-flow breakeven in 2025.","Launched DAXXIFY for cervical dystonia (CD), entering $2.7B U.S. therapeutic neurotoxin market; 78% commercial lives covered."],"urls":{"canonical":"https://secwatch.observer/filing/0001479290-24-000099","json":"https://secwatch.observer/filing/0001479290-24-000099.json","markdown":"https://secwatch.observer/filing/0001479290-24-000099.md","text":"https://secwatch.observer/filing/0001479290-24-000099.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479290/000147929024000099/0001479290-24-000099-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479290/000147929024000099/rvnc-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:31:23.683168+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"59eec9a42e4f576a00905e598c1d368fc310c5ed","claim":"Revance Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"Total net revenue for the first quarter ended March 31, 2024 was $51.9 million compared to $45.8 million for the same period last year, representing an increase of 13%, due to an increase in DAXXIFY sales volume.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929024000099/0001479290-24-000099-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"59eec9a42e4f576a00905e598c1d368fc310c5ed","claim":"Revance Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"Net loss from continuing operations for the first quarter ended March 31, 2024 was $49.5 million compared to $48.5 million for the same period in 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929024000099/0001479290-24-000099-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}